Switch theme
Sign up to access all valuation multiples
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company’s therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson’s disease, THN201 for the treatment of neurocognitive disorders in Alzheimer’s disease and THN101 for neuropathic pain.
2013
15
LTM Revenue n/a
LTM EBITDA n/a
$4.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Theranexus has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Theranexus achieved revenue of n/a and an EBITDA of -$7.8M.
Theranexus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Theranexus valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | -$6.0M | -$4.2M | XXX | XXX | XXX |
| Gross Margin | -Infinity% | NaN% | XXX | XXX | XXX |
| EBITDA | -$7.8M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | NaN% | XXX | XXX | XXX |
| Net Profit | -$8.8M | -$7.1M | XXX | XXX | XXX |
| Net Margin | -Infinity% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | $3.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Theranexus's stock price is EUR 0 (or $0).
Theranexus has current market cap of EUR 3.3M (or $3.6M), and EV of EUR 4.5M (or $4.8M).
See Theranexus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8M | $3.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Theranexus has market cap of $3.6M and EV of $4.8M.
Theranexus's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Theranexus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Theranexus and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTheranexus's NTM/LTM revenue growth is n/a
Theranexus's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Theranexus's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Theranexus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Theranexus and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theranexus acquired XXX companies to date.
Last acquisition by Theranexus was XXXXXXXX, XXXXX XXXXX XXXXXX . Theranexus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Theranexus founded? | Theranexus was founded in 2013. |
| Where is Theranexus headquartered? | Theranexus is headquartered in France. |
| How many employees does Theranexus have? | As of today, Theranexus has 15 employees. |
| Is Theranexus publicy listed? | Yes, Theranexus is a public company listed on PAR. |
| What is the stock symbol of Theranexus? | Theranexus trades under ALTHX ticker. |
| When did Theranexus go public? | Theranexus went public in 2017. |
| Who are competitors of Theranexus? | Similar companies to Theranexus include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Theranexus? | Theranexus's current market cap is $3.6M |
| Is Theranexus profitable? | Yes, Theranexus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
